3ŒŽ29“ú(ç«)@15:30~17:30@G‰ïê パシフィコ横浜 会è°ã‚»ãƒ³ã‚¿ãƒ¼ã€€3F 315 GS05 患者ã®QOL改善を目指ã—ãŸè–¬å¦åŸºç¤Žç ”究 Basic Research in Pharmacy for Improvement of Patient’s Quality of Life ã‚ªãƒ¼ã‚¬ãƒŠã‚¤ã‚¶ãƒ¼ï¼šç¯ ç”° 康晴ã€è¥¿æ¾¤ 由紀彦 GS05-1 乳癌ã«ãŠã‘るトラスツズマブè€æ€§åŒ–ã®è¦å› 解æžã¨ãã®å…‹æœã«å‘ã‘ãŸæ–°è¦ã‚¢ãƒ—ãƒãƒ¼ãƒ Mechanisms of Trastuzumab resistance in breast cancer and novel potential therapeutics ƒVƒ“ƒ|ƒWƒXƒg F â—‹æ¦ç”° é”明ã€ç¥žå´Ž 浩åã€å®— 淳一ã€å±±æœ¬ 寛斉ã€åŒ—æ‘ ä½³ä¹…ã€è±Šå²¡ 伸一ã€ä¸‰å¥½ 新一郎ã€åƒå ‚ å¹´æ˜ GS05-2 疼痛時ã«ãŠã‘る脳内ã®è„‚肪酸コントãƒãƒ¼ãƒ«ã«å¯¾ã™ã‚‹ã‚¢ã‚¹ãƒˆãƒã‚µã‚¤ãƒˆã®é–¢ä¸Ž Involvement of astrocyte control brain fatty acid under pain condition ƒVƒ“ƒ|ƒWƒXƒg F ○相澤 風花ã€è¥¿ä¸ å´‡ã€å±±ä¸‹ ç¢çŸ¢ã€ä¸æœ¬ 賀寿夫ã€å°å±± 豊ã€ç³Ÿè°· å²ä»£ã€å¾³å±± å°šå¾ GS05-3 水毒鑑別ã®ãŸã‚ã®ä½“æˆåˆ†ã«ãŠã‘ã‚‹å®¢è¦³çš„äºˆæ¸¬å› åã¨è‡ªè¦šç—‡çŠ¶ã®é–¢é€£ã«ã¤ã„㦠Study on correlation between objective predictors in body composition and subjective symptoms for the diagnisis of suidoku ƒVƒ“ƒ|ƒWƒXƒg F â—‹æ‘上 綾ã€è²æ²¼ 茂三郎ã€ç‘žæ…¶å±± ã«ã„ãªã€å°æž— 大介ã€çªªç”° æ•å¤«ã€å³¶æ·» 隆雄 GS05-4 ç‹èŽç¸®æ€§å´ç´¢ç¡¬åŒ–ç—‡ã«é–¢é€£ã™ã‚‹ã‚·ã‚°ãƒž1å—容体変異体ã®ç¥žçµŒç´°èƒžæ¯’性ã®æ¤œè¨Ž The neurotoxic mechanisms of ALS-related Sigma-1 receptor mutation ƒVƒ“ƒ|ƒWƒXƒg F â—‹ç¯ ç”° 康晴ã€ç”°é ç§€ç« ã€ç¦æ°¸ æµ©å¸ GS05-5 脳虚血ã«ä¼´ã†TIGARã®ç™ºç¾ã«ã¯æ´»æ€§é…¸ç´ 種ã¨ã‚°ãƒ«ã‚³ãƒ¼ã‚¹ä»£è¬é–¢é€£ãƒ›ãƒ«ãƒ¢ãƒ³ãŒé–¢ä¸Žã™ã‚‹ I/R-induced upregulation of TIGAR in brain is mediated by ROS and hormones involved in glucose metabolism ƒVƒ“ƒ|ƒWƒXƒg F â—‹å« ç¾ŽçŽ²ã€æŽ 梅ã€é»„ å·§ã€éŸ“ å³°ã€é¡§ 錦è¯ã€è¬ 佳明ã€éŸ“ 蓉ã€ç§¦ æ£ç´…ã€å‘¨ 智鵬 GS05-6 éºä¼æ€§è…Žç‚Žã‚¢ãƒ«ãƒãƒ¼ãƒˆç—‡å€™ç¾¤ã®æ—©æœŸç—…æ…‹ãŠã‚ˆã³åŽŸå› タンパク質標的ã«ã‚ˆã‚‹å‰µè–¬ã«å‘ã‘ãŸåŸºç¤Žç ”究 Clarify the intracellular stress response in early-stage Alport Syndrome (AS) and establish an evaluation system for intracellular regulation of COL4A5, the causal protein for AS ƒVƒ“ƒ|ƒWƒXƒg F ○大町 紘平ã€SUICO Mary Annã€é¦–è—¤ 剛ã€ç”²æ– 広文 ŒŸõƒy[ƒW‚É–ß‚é